Discovery, Development, Inventions, and Patent Trends on Mobocertinib Succinate: The First-in-Class Oral Treatment for NSCLC with EGFR Exon 20 Insertions

Subtypes of EGFR and HER2 mutant metastatic NSCLC influence response to immune checkpoint inhibitors

(2021) Sally CM. Lau et al.   Clinical Lung Cancer

Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries

(2021) Hyuna Sung et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Response to standard therapies and comprehensive genomic analysis for patients with lung adenocarcinoma with EGFR exon 20 insertions

(2021) Noura J. Choudhury et al.   CLINICAL CANCER RESEARCH

Synthetic molecules as DprE1 inhibitors: A patent review

(2021) Mohd. Imran et al.   EXPERT OPINION ON THERAPEUTIC PATENTS

Epidemiological and clinical burden of EGFR Exon 20 insertion in advanced non-small cell lung cancer: A systematic literature review

(2021) Heather Burnett et al.   PLoS One

Activity and Safety of Mobocertinib (TAK-788) in Previously Treated Non-Small Cell Lung Cancer With EGFR Exon 20 Insertion Mutations From a Phase 1/2 Trial

(2021) Gregory J. Riely et al.   Cancer Discovery

Mobocertinib (TAK-788): A Targeted Inhibitor of EGFR Exon 20 Insertion Mutants in Non-Small Cell Lung Cancer

(2021) Francois Gonzalvez et al.   Cancer Discovery

Afatinib as First-Line Treatment in Asian Patients with EGFR Mutation-Positive NSCLC: A Narrative Review of Real-World Evidence

(2021) Shun Lu et al.   ADVANCES IN THERAPY

Amivantamab: First Approval

(2021) Yahiya Y. Syed   DRUGS

Osimertinib in EGFR-Mutated Lung Cancer: A Review of the Existing and Emerging Clinical Data

(2021) Chung-Shien Lee et al.   OncoTargets and Therapy

Mobocertinib: A Potential Treatment for NSCLC with EGFR Exon 20 Insertions

(2021) Jose M. Pacheco   Cancer Discovery

Effects of Itraconazole and Rifampin on the Pharmacokinetics of Mobocertinib (TAK‐788), an Oral Epidermal Growth Factor Receptor Inhibitor, in Healthy Volunteers

(2021) Steven Zhang et al.   Clinical Pharmacology in Drug Development

Single‐Dose Pharmacokinetics and Tolerability of the Oral Epidermal Growth Factor Receptor Inhibitor Mobocertinib (TAK‐788) in Healthy Volunteers: Low‐Fat Meal Effect and Relative Bioavailability of 2 Capsule Products

(2021) Steven Zhang et al.   Clinical Pharmacology in Drug Development

Trends in the development of remdesivir based inventions against COVID-19 and other disorders: A patent review

(2021) Mohd. Imran et al.   Journal of Infection and Public Health

Innovations and Patent Trends in the Development of USFDA Approved Protein Kinase Inhibitors in the Last Two Decades

(2021) Mohd. Imran et al.   Pharmaceuticals

Discovery, Development, and Patent Trends on Molnupiravir: A Prospective Oral Treatment for COVID-19

(2021) Mohd. Imran et al.   MOLECULES

Treatment Outcomes and Safety of Mobocertinib in Platinum-Pretreated Patients With EGFR Exon 20 Insertion–Positive Metastatic Non–Small Cell Lung Cancer

(2021) Caicun Zhou et al.   JAMA Oncology

Anlotinib as a molecular targeted therapy for tumors (Review)

(2020) Yi Gao et al.   Oncology Letters

EGFR exon 20 insertion mutations in non-small cell lung cancer

(2020) Fenfang Wang et al.   Translational Cancer Research

The Effect of Advances in Lung-Cancer Treatment on Population Mortality

(2020) Nadia Howlader et al.   NEW ENGLAND JOURNAL OF MEDICINE

Extensive functional evaluation of exon 20 insertion mutations of EGFR

(2020) Takeshi Hirose et al.   LUNG CANCER

Non–Small Cell Lung Cancer: Epidemiology, Screening, Diagnosis, and Treatment

(2019) Narjust Duma et al.   MAYO CLINIC PROCEEDINGS

Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors in non-small cell lung cancer harboring uncommon EGFR mutations: Focus on afatinib

(2019) Ashiq Masood et al.   SEMINARS IN ONCOLOGY

Clinical evaluation of dacomitinib for the treatment of metastatic non-small cell lung cancer (NSCLC): current perspectives

(2019) Daniele Lavacchi et al.   Drug Design Development and Therapy

Targeting EGFR in Lung Cancer: Current Standards and Developments

(2018) Asunción Díaz-Serrano et al.   DRUGS

Recognising Lung Cancer in Primary Care

(2018) Stephen H. Bradley et al.   ADVANCES IN THERAPY

EGFR exon 20 insertion in lung adenocarcinomas among Hispanics (geno1.2-CLICaP)

(2018) Andrés F. Cardona et al.   LUNG CANCER

Risk factors for lung cancer worldwide

(2016) Jyoti Malhotra et al.   EUROPEAN RESPIRATORY JOURNAL

Pharmaceutical salts: A summary on doses of salt formers from the Orange Book

(2013) C. Saal et al.   EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES

EGFR exon 20 insertion mutations in non-small-cell lung cancer: preclinical data and clinical implications

(2011) Hiroyuki Yasuda et al.   LANCET ONCOLOGY